Business Context and Reporting Period
Company: ILLUMINA, INC. (ILMN)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Fiscal Quarter ended September 28, 2025 (Q3 2025)
Business Overview: Illumina is a global leader in DNA sequencing and array-based technologies serving research, clinical, and applied markets. Following the spin-off of GRAIL in June 2024, the company now operates as a single reportable segment, "Core Illumina."
Key Financial Metrics
| Metric (in millions) | Q3 2025 | Q3 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Total Revenue | $1,084 | $1,080 | $3,184 | $3,268 |
| Gross Profit | $733 | $745 | $2,111 | $2,133 |
| Gross Margin | 67.6% | 68.9% | 66.3% | 65.3% |
| Operating Income | $227 | $741 | $606 | ($1,008) |
| Net Income | $150 | $705 | $516 | ($1,410) |
| Diluted EPS | $0.98 | $4.42 | $3.29 | ($8.86) |
| Cash & Equivalents | $1,050 | $1,127 | $1,050 | $1,048 |
| Short-term Investments | $228 | $93 | $228 | $93 |
| Total Debt (Current + Non-Current) | $1,992 | $1,989 | $1,992 | $1,989 |
| Operating Cash Flow (YTD) | $758 | $473 | $758 | $473 |
Material Changes vs. Prior Period
- Revenue Stability: Q3 2025 revenue remained flat at $1,084 million compared to Q3 2024. YTD 2025 revenue decreased 3% to $3,184 million, primarily due to the exclusion of GRAIL service revenue following the June 2024 spin-off and a decline in instrument shipments.
- Profitability Improvement: Operating income for YTD 2025 was $606 million, a significant turnaround from the $1,008 million operating loss in YTD 2024. The prior year loss was heavily influenced by a $1.889 billion goodwill and intangible impairment charge related to GRAIL and a $474 million legal settlement gain in 2024 that did not recur.
- Margin Pressure: Gross margin decreased slightly in Q3 2025 (67.6% vs 68.9%) and YTD 2025 (66.3% vs 65.3% adjusted for GRAIL spin-off) due to higher tariff costs, a $23 million intangible asset impairment, and increased inventory reserves.
- Expense Management: Research and Development (R&D) expenses decreased 9% in Q3 2025 and 20% YTD 2025 due to cost reduction initiatives. Selling, General, and Administrative (SG&A) expenses increased 16% in Q3 2025, largely driven by a $52 million unfavorable remeasurement of contingent consideration liabilities related to GRAIL.
- Tax Rate Volatility: The effective tax rate for YTD 2025 was 27.2%, compared to a negative rate in YTD 2024. This increase includes a one-time $42 million valuation allowance against deferred tax assets due to new U.S. tax legislation signed in July 2025.
Guidance, Outlook, and Risks
- Pending Acquisition: Illumina agreed to acquire SomaLogic and certain assets from Standard BioTools for $350 million in cash, plus potential milestone payments up to $75 million. The deal is expected to close in the first half of 2026, subject to regulatory approvals.
- China Regulatory Risk: Illumina was added to China's "unreliable entities list" in Q1 2025, prohibiting the export of sequencing instruments into China. This has resulted in a revenue decrease of $23 million in Q3 2025 and $41 million YTD 2025 from the Greater China region.
- Tariff Impact: New tariffs enacted in April 2025 are impacting costs, particularly regarding imports from Singapore. Management aims to partially mitigate these costs in 2025 through supply chain optimization and pricing actions, with full mitigation targeted for 2026.
- Legal Proceedings: Multiple shareholder derivative lawsuits and securities class actions remain pending regarding the GRAIL acquisition. While one derivative action was settled in principle with no payment, others are ongoing with motions to dismiss pending.
- Capital Allocation: The company continues an aggressive share repurchase program. As of September 28, 2025, $684 million remained available under a $1.5 billion authorization. YTD 2025 repurchases totaled $700 million.
Investor Verification Checklist
- China Exposure: Verify the extent of ongoing revenue loss from the Greater China region and the effectiveness of mitigation strategies against the "unreliable entities" ban.
- Tariff Mitigation: Assess the company's ability to pass tariff costs to customers or absorb them without further margin compression in 2026.
- SomaLogic Integration: Monitor regulatory approval progress for the SomaLogic acquisition and the strategic fit within the multiomics portfolio.
- GRAIL Contingent Liabilities: Track the volatility of the contingent consideration liability (CVRs) related to GRAIL revenues, which significantly impacts SG&A expenses.
- Instrument Demand: Evaluate trends in high- and mid-throughput instrument shipments, which have been constrained by customer capital budgets and cash flow concerns.